tirzepatide and mash Newly released phase IIb 48-week liver biopsy data on #tirzepatide in #MASH. 73.9% resolution of with no worsening of fibrosis on 15 mg. Secondary endpoint ⬇️ fibrosis by >1 stage FDA approves tirzepatide, Eli Lilly's

For the vast majority of people, the benefits of improved metabolic health and weight reduction far outweigh the short-lived discomfort of the adjustment period

What triggers food noise most

Sermorelin is a Growth Hormone Releasing Hormone (GHRH) that stimulates directly binds to the pituitary gland to release growth hormone

Incidence and Prevalence of Atrial Fibrillation Among Individuals With Chronic Kidney Disease

Protocol Design Personalized dosing, injection schedule, and combination strategy

84 The weight loss achieved with health behavioral changes is usually 3%5% of bodyweight, and it varies substantially based on the individual's biological and psychosocial factors